Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Check Point Software Technologies Ltd. (NASDAQ: CHKP) shares gained $2.90 to close at $56.40 a share Thursday. The stock traded between $54.55 and $57.11 on volume of 4.24 million shares traded. The company revenues were $340.2 million for the second quarter of 2013, an increase of 4 percent when compared to a year ago. Shares of Check Point Software Technologies have gained approximately 18.5 percent year-to-date.
Get more information on Check Point and free access to the in-depth equity report at:
www.FiveStarEquities.com/CHKP
Ericsson (NASDAQ: ERIC) shares declined $0.58 to close at $11.60 a share Thursday. The stock traded between $11.38 and $11.71 on volume of 10.85 million shares traded. The company reported sales were 55.3 billion kronor ($8.4 billion) for the second quarter of 2013. According to data from Bloomberg the average estimates of analysts called for 56 billion kronor. Shares of Ericsson have gained approximately 14.5 percent year-to-date.
Get more information on Ericsson and free access to the in-depth equity report at:
www.FiveStarEquities.com/ERIC
Johnson Controls Inc. (NYSE: JCI) shares spiked $3.09 to close at $40.43 a share Thursday. The stock traded between $39.13 and $41.02 on volume of 17.02 million shares traded. The company reported earnings for the fiscal third quarter surged 32 percent year-over-year. Shares of Johnson Controls have gained approximately 33.5 percent year-to-date.
Get more information on Johnson Controls and free access to the in-depth equity report at:
www.FiveStarEquities.com/JCI
Transition Therapeutics Inc. (NASDAQ: TTHI) shares soared $1.16 to close at $56.37 a share Thursday. The stock traded between $3.95 and $4.60 on volume of 3.96 million shares traded. The company announced that the FDA has granted Fast Track Designation to the development program for ELND005. Shares of Transition Therapeutics have gained approximately 83.6 percent year-to-date.
Get more information on Transition Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/TTHI
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com